Clinical evidence for three distinct gastric cancer subtypes: Time for a new approach

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Bittoni, Alessandro ^a   Scartozzi, Mario ^a   Giampieri, Riccardo ^a   Faloppi, Luca ^a   Bianconi, Maristella ^a   Mandolesi, Alessandra ^a   Del Prete, Michela ^a   Pistelli, Mirco ^a   Cecchini, Luca ^a   Bearzi, Italo ^a   Cascinu, Stefano ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CAPECITABINE; CISPLATIN; DOCETAXEL; EPIRUBICIN; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MITOMYCIN; OXALIPLATIN; PACLITAXEL; PLATINUM COMPLEX; TAXANE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTION; PROGRESSION FREE SURVIVAL; STOMACH CANCER; STOMACH SURGERY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATINUM; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 84893187039     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078544     Document Type: Article

References (19)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011). Global cancer statistics. CA Cancer J Clin 61:69-90.
2. Peek RMJ, Blaser MJ (2002). Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer 2:28-37.
3. You WC, Blot WJ, Li JY, Chang YS, Jin ML, et al. (1993). Precancerous gastric lesions in a population at high risk of stomach cancer. Cancer Res 53:1317-21. (Pubitemid 23097109)
4. Carneiro F, Huntsman DG, Smyrk TC, Owen DA, Seruca R, et al. (2004). Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and it's implications for patient screening. J Pathol 203:681-7. (Pubitemid 38714105)
5. Marrelli D, Roviello F, de Manzoni G, Morgagni P, Di Leo A, et al. (2002). Different patterns of recurrence in gastric cancer depending on Lauren's histologic type: longitudinal study. World J Surg 26: 1160-5. (Pubitemid 36920276)
6. Liu L, Wang ZW, Ji J, Zhang JN, Yan M, et al. (2013). A Cohort Study and Meta-Analysis between Histopathological Classification and Prognosis of Gastric Carcinoma. Anticancer Agents Med Chem 13:2: 227-234.
7. Shah MA, Kelsen DP (2010). Gastric cancer: A primer on the epidemiology and biology of the disease and an overview of the medical management of advanced disease. J Natl Compr Canc Netw 8:437-47.
8. Shah MA, Khanin R, Tang L, Janjigian YY, Klimstra DS, et al. (2011). Molecular Classification of Gastric Cancer: A New Paradigm. Clin Cancer Res 17:2693-2701.
9. Ajani JA, Rodriguez G, Bodoky V, Moiseyenko V, Lichinitser M, et al. (2009). Multicenter phase III comparison of cisplatin/S-1 (CS) with cisplatin/5-FU (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS): secondary and subset analyses [abstract]. J Clin Oncol 27(Suppl 1):Abstract 4511.
10. Shah MA, Jhawer M, Ilson DH, Lefkowitz RA, Robinson E, et al. (2011). Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil With Bevacizumab in Patients With Metastatic Gastroesophageal Adenocarcinoma. J Clin Oncol 29(7):868-874.
11. Sakaguchi T, Watanabe A, Sawada H, Yamada Y, Tatsumi M, et al. (1998). Characteristics and clinical outcome of proximal third gastric cancer. J Am Coll Surg 187:352-357. (Pubitemid 28467609)
12. Kattan MW, Karpeh MS, Mazumdar M, Brennan MF (2003). Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. J Clin Oncol 21:3647-3650. (Pubitemid 46594058)
13. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, et al. (2010). Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2- positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 376:687-697.
14. Tanner M, Hollmen M, Junttila TT, Kapanen AI, Tommola S, et al. (2005). Amplification of HER-2 in gastric carcinoma: association with Topoisomerase II-alpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 16: 273-78. (Pubitemid 40309309)
15. Smalley SR, Benedetti JK, Haller DG, Hundahl SA, Estes NC, et al. (2012). Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol 30(19):2327-33. Epub 2012 May 14.
16. Bajetta E, Floriani E, Di Bartolomeo M, Labianca R, Falcone A, et al. (2012). Itaca-s (intergroup trial of adjuvant chemotherapy in adenocarcinoma of the stomach) trial: comparison of a sequential treatment with irinotecan (cpt-11)+5- fluorouracil (5fu)/folinic acid (lv) followed by docetaxel and cisplatin versus a 5-fu/lvregimen as postoperative treatment for radically resected gastric cancer. Tumori (supp) 13; 3: S1.
17. Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, et al. (2011). Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 29(30):3968-76. Epub 2011 Aug.
18. Scartozzi M, Bittoni A, Pistelli M, Galizia E, Berardi R, et al. (2009). Toward molecularly selected chemotherapy for advanced gastric cancer: state of the art and future perspectives. Cancer Treat Rev 35(5):451-62. Epub 2009 May 20.
19. Kamoshida S, Shiogama K, Shimomura R, Inada K, Sakurai Y, et al. (2005). Immunohistochemical demonstration of fluoropyrimidine-metabolizing enzymes in various types of cancer. Oncol Rep 14(5):1223-30.